Please use this identifier to cite or link to this item:
Title: Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Authors: Laguno, M
Von Wichmann, M A
Van den Eynde, E
Navarro, J
Cifuentes, C
Murillas, J
Veloso, S
Martínez-Rebollar, M
Guardiola, J M
Jou, A
Gómez-Sirvent, J L
Cervantes, M
Pineda, J A
López-Calvo, S
Carrero, A
Montes, M L
Deig, E
Tapiz, A
Ruiz-Mesa, J D
Cruceta, A
de Lazzari, E
Mallolas, J
Keywords: HCV genotype 1;HIV–HCV experienced patients;PEG-IFN/RBV+BOC therapy;Re-treatment
metadata.dc.subject.mesh: Adult
Antiviral Agents
Drug Therapy, Combination
HIV Infections
Hepatitis C
Middle Aged
Polyethylene Glycols
Prospective Studies
Recombinant Proteins
Treatment Outcome
Viral Nonstructural Proteins
Issue Date: 1-Nov-2016
Abstract: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC+pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC+PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferon-free therapies are not available yet.
metadata.dc.identifier.doi: 10.1016/j.ijid.2016.10.028
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons